Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases

The Lancet Gastroenterology & Hepatology - Tập 6 Số 9 - Trang 743-753 - 2021
Mohammed Eslam1, Aijaz Ahmed2, Jean‐Pierre Després3,4,5, Vivekanand Jha6,7,8, Jason C. G. Halford9, Jack Tan Wei Chieh10, David C.H. Harris11, Masaomi Nangaku12, Stephen Colagiuri13, Giovanni Targher14, Shashank Joshi15, Christopher D. Byrne16,17, Kamlesh Khunti18,19, Mindie H. Nguyen20,21, Robert G. Gish22, Jacob George1
1Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia
2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA
3Centre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada
4Department of Kinesiology, Faculty of Medicine, Université Laval, Québec, QC, Canada
5Université Laval, Québec, QC, Canada
6George Institute for Global Health, UNSW, New Delhi, India
7Manipal Academy of Higher Education, Manipal, India
8School of Public Health, Imperial College London, London, UK
9School of Psychology, University of Leeds, Leeds, UK
10Department of Cardiovascular Medicine, National Heart Centre Singapore, Singapore
11Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia
12The University of Tokyo Graduate School of Medicine, Tokyo, Japan
13Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
14Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
15Lilavati Hospital and Research Centre, Mumbai, India
16Nutrition and Metabolism, Faculty of Medicine, University of Southampton, UK
17Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, UK
18Diabetes Research Centre, University of Leicester, Leicester, UK
19Leicester General Hospital, Leicester, UK
20Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA
21Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA
22Division of Gastroenterology and Hepatology, Loma Linda University, Loma Linda, CA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

2018

2014

Barnett, 2012, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Lancet, 380, 37, 10.1016/S0140-6736(12)60240-2

Chudasama, 2020, Healthy lifestyle and life expectancy in people with multimorbidity in the UK Biobank: a longitudinal cohort study, PLoS Med, 17, 10.1371/journal.pmed.1003332

Marengoni, 2011, Aging with multimorbidity: a systematic review of the literature, Ageing Res Rev, 10, 430, 10.1016/j.arr.2011.03.003

Kingston, 2018, Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model, Age Ageing, 47, 374, 10.1093/ageing/afx201

Eslam, 2019, Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology, Nat Rev Gastroenterol Hepatol, 17, 40, 10.1038/s41575-019-0212-0

Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012

Shiha, 2021, Redefining fatty liver disease: an international patient perspective, Lancet Gastroenterol Hepatol, 6, 73, 10.1016/S2468-1253(20)30294-6

Eslam, 2020, The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, Hepatol Int, 14, 889, 10.1007/s12072-020-10094-2

Mendez-Sanchez, 2021, The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease, Lancet Gastroenterol Hepatol, 6, 65, 10.1016/S2468-1253(20)30340-X

Shiha, 2021, Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa, Lancet Gastroenterol Hepatol, 6, 57, 10.1016/S2468-1253(20)30213-2

Zheng, 2020, From NAFLD to MAFLD: a “redefining” moment for fatty liver disease, Chin Med J (Engl), 133, 2271, 10.1097/CM9.0000000000000981

Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367

2016, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease, Obes Facts, 9, 65, 10.1159/000443344

Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 40, 1387, 10.1002/hep.20466

Fracanzani, 2008, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002/hep.22429

Lazarus, 2020, A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe, J Hepatol, 72, 14, 10.1016/j.jhep.2019.08.027

Lin, 2020, Comparison of MAFLD and NAFLD diagnostic criteria in real world, Liver Int, 40, 2082, 10.1111/liv.14548

Yamamura, 2020, MAFLD identifies patients with significant hepatic fibrosis better than NAFLD, Liver Int, 40, 3018, 10.1111/liv.14675

Niriella, 2021, Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study, PLoS One, 16, 10.1371/journal.pone.0245762

Lee, 2020, Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study, Clin Gastroenterol Hepatol

Sun, 2021, MAFLD and risk of CKD, Metabolism, 115, 10.1016/j.metabol.2020.154433

Cleveland, 2019, Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample: the CARDIA study, J Gen Intern Med, 34, 2772, 10.1007/s11606-019-05340-9

Singh, 2020, Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort, Dig Dis Sci, 65, 978, 10.1007/s10620-019-05700-9

Zhang, 2019, Awareness and knowledge of nonalcoholic fatty liver disease among office employees in Beijing, China, Dig Dis Sci, 64, 708, 10.1007/s10620-018-5389-5

Wieland, 2015, Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk, J Clin Gastroenterol, 49, e6, 10.1097/MCG.0000000000000075

Le, 2019, Nonalcoholic fatty liver disease and renal function impairment: a cross-sectional population-based study on its relationship from 1999 to 2016, Hepatol Commun, 3, 1334, 10.1002/hep4.1408

Le, 2020, Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016, J Intern Med, 287, 711, 10.1111/joim.13035

Mlynarsky, 2016, Non-alcoholic fatty liver disease is not associated with a lower health perception, World J Gastroenterol, 22, 4362, 10.3748/wjg.v22.i17.4362

Stewart, 2012, Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease, Clin Liver Dis, 16, 615, 10.1016/j.cld.2012.05.007

Goh, 2016, Perceptions of non-alcoholic fatty liver disease - an Asian community-based study, Gastroenterol Rep (Oxf), 4, 131, 10.1093/gastro/gov047

Fouad, 2021, Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists, J Hepatol, 74, 1254, 10.1016/j.jhep.2020.12.035

Alem, 2021, Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback, J Hepatol, 74, 1261, 10.1016/j.jhep.2021.01.022

Spearman, 2021, The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD, J Hepatol, 74, 1256, 10.1016/j.jhep.2021.01.015

Clayton, 2021, From NAFLD to MAFLD: nurse and allied health perspective, Liver Int, 41, 683, 10.1111/liv.14788

Mantovani, 2020, Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals, Gut, 70, 962, 10.1136/gutjnl-2020-322572

Yamazaki, 2015, Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes, Diabetes Care, 38, 1673, 10.2337/dc15-0140

Sung, 2013, Resolution of fatty liver and risk of incident diabetes, J Clin Endocrinol Metab, 98, 3637, 10.1210/jc.2013-1519

Afolabi, 2018, The relationship between glycaemic control and non-alcoholic fatty liver disease in Nigerian type 2 diabetic patients, J Natl Med Assoc, 110, 256

Targher, 2007, Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients, Diabetes Care, 30, 2119, 10.2337/dc07-0349

Mantovani, 2016, Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring, Diabetes Care, 39, 1416, 10.2337/dc16-0091

Targher, 2008, Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients, Diabetologia, 51, 444, 10.1007/s00125-007-0897-4

Mantovani, 2017, Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes, J Diabetes Complications, 31, 1021, 10.1016/j.jdiacomp.2017.01.024

Björkström, 2017, Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 15, 1461, 10.1016/j.cgh.2017.04.040

Kim, 2013, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, 57, 1357, 10.1002/hep.26156

Dai, 2017, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis, Medicine (Baltimore), 96, 10.1097/MD.0000000000008179

Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021

Sarin, 2020, Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission, Lancet Gastroenterol Hepatol, 5, 167, 10.1016/S2468-1253(19)30342-5

Bazick, 2015, Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD, Diabetes Care, 38, 1347, 10.2337/dc14-1239

Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265

Ertle, 2011, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis, Int J Cancer, 128, 2436, 10.1002/ijc.25797

de Marco, 1999, Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study, Diabetes Care, 22, 756, 10.2337/diacare.22.5.756

Bril, 2017, Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action, Diabetes Care, 40, 419, 10.2337/dc16-1787

Oni, 2013, A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?, Atherosclerosis, 230, 258, 10.1016/j.atherosclerosis.2013.07.052

Zhou, 2018, Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis, Eur J Gastroenterol Hepatol, 30, 631, 10.1097/MEG.0000000000001075

Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034

Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014

Henson, 2020, Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 51, 728, 10.1111/apt.15660

Zou, 2017, Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes, Intern Med J, 47, 1147, 10.1111/imj.13549

Abdeldyem, 2017, Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome, J Clin Lipidol, 11, 915, 10.1016/j.jacl.2017.04.115

López-Suárez, 2011, Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase, Eur J Gastroenterol Hepatol, 23, 1011, 10.1097/MEG.0b013e32834b8d52

Aneni, 2015, Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk, J Hypertens, 33, 1207, 10.1097/HJH.0000000000000532

Allen, 2019, The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity—a longitudinal cohort study, J Hepatol, 71, 1229, 10.1016/j.jhep.2019.08.018

Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, 10.1371/journal.pmed.1001680

Mantovani, 2018, Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis, Metabolism, 79, 64, 10.1016/j.metabol.2017.11.003

Park, 2019, Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study, J Intern Med, 286, 711, 10.1111/joim.12964

Vilar-Gomez, 2017, Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 45, 332, 10.1111/apt.13860

Chinnadurai, 2019, Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease, Nephrol Dial Transplant, 34, 449, 10.1093/ndt/gfx381

Chinnadurai, 2019, Increased risk for cardiovascular events in patients with diabetic kidney disease and non-alcoholic fatty liver disease, Nephron, 141, 24, 10.1159/000493472

Önnerhag, 2019, Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities, Clin Res Hepatol Gastroenterol, 43, 542, 10.1016/j.clinre.2019.02.004

Sperling, 2015, The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome, J Am Coll Cardiol, 66, 1050, 10.1016/j.jacc.2015.06.1328

Eslam, 2020, A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement, J Hepatol, 73, 202, 10.1016/j.jhep.2020.03.039

Daniels, 2019, ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis, Hepatology, 69, 1075, 10.1002/hep.30163

Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346

Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496

Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178

Siddiqui, 2019, Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 17, 156, 10.1016/j.cgh.2018.04.043

Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005

Dubé, 2011, Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide, Diabetologia, 54, 1147, 10.1007/s00125-011-2065-0

Saint-Pierre, 2018, Multidisciplinary collaboration in primary care: a systematic review, Fam Pract, 35, 132, 10.1093/fampra/cmx085

Vanfleteren, 2016, Management of chronic obstructive pulmonary disease beyond the lungs, Lancet Respir Med, 4, 911, 10.1016/S2213-2600(16)00097-7

Lim, 2014, Multidisciplinary approach to management of maternal asthma (MAMMA): a randomized controlled trial, Chest, 145, 1046, 10.1378/chest.13-2276

Marzolini, 2009, Feasibility and effects of a group-based resistance and aerobic exercise program for individuals with severe schizophrenia: a multidisciplinary approach, Ment Health Phys Act, 2, 29, 10.1016/j.mhpa.2008.11.001

Kornelius, 2015, The diabetes shared care program and risks of cardiovascular events in type 2 diabetes, Am J Med, 128, 977, 10.1016/j.amjmed.2015.03.025

Montesi, 2016, Long-term weight loss maintenance for obesity: a multidisciplinary approach, Diabetes Metab Syndr Obes, 9, 37

Hamdy, 2017, Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study, BMJ Open Diabetes Res Care, 5, 10.1136/bmjdrc-2016-000259

Phelan, 2006, Are the eating and exercise habits of successful weight losers changing?, Obesity (Silver Spring), 14, 710, 10.1038/oby.2006.81

Thomas, 2014, Weight-loss maintenance for 10 years in the National Weight Control Registry, Am J Prev Med, 46, 17, 10.1016/j.amepre.2013.08.019

Caranti, 2007, Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents, Metabolism, 56, 1293, 10.1016/j.metabol.2007.05.004

Monzavi, 2006, Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention, Pediatrics, 117, e1111, 10.1542/peds.2005-1532

Balagopal, 2005, Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents, J Clin Endocrinol Metab, 90, 6192, 10.1210/jc.2004-2427

Chen, 2006, Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children, Metabolism, 55, 871, 10.1016/j.metabol.2006.03.001

Moolla, 2019, A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health, Frontline Gastroenterol, 10, 337, 10.1136/flgastro-2018-101155

Lee, 2019, Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 17, 1040, 10.1016/j.cgh.2018.10.017

Say, 2003, The importance of patient preferences in treatment decisions—challenges for doctors, BMJ, 327, 542, 10.1136/bmj.327.7414.542

Coulter, 2005, What do patients and the public want from primary care?, BMJ, 331, 1199, 10.1136/bmj.331.7526.1199

Coulter, 2007, Effectiveness of strategies for informing, educating, and involving patients, BMJ, 335, 24, 10.1136/bmj.39246.581169.80

Group, 2002, The Diabetes Prevention Program (DPP): description of lifestyle intervention, Diabetes Care, 25, 2165, 10.2337/diacare.25.12.2165

Eslam, 2019, Genetic insights for drug development in NAFLD, Trends Pharmacol Sci, 40, 506, 10.1016/j.tips.2019.05.002

Eslam, 2020, MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease, Gastroenterology, 158, 1999, 10.1053/j.gastro.2019.11.312

Park, 2016, Adaptive randomization of neratinib in early breast cancer, N Engl J Med, 375, 11, 10.1056/NEJMoa1513750

Berry, 2015, The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research, Mol Oncol, 9, 951, 10.1016/j.molonc.2015.02.011

Vassal, 2015, Creating a unique, multi-stakeholder paediatric oncology platform to improve drug development for children and adolescents with cancer, Eur J Cancer, 51, 218, 10.1016/j.ejca.2014.10.029

Berry, 2015, The platform trial: an efficient strategy for evaluating multiple treatments, JAMA, 313, 1619, 10.1001/jama.2015.2316